This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Amicus, Amarin, Oncothyreon

The study also measured, as a pre-defined secondary endpoint, the absolute percent change in kidney GL3 from baseline to six months. The result: Amigal 41% reduction compared to placebo 6% reduction. Again, the difference was not statistically significant but it sure seems like Amigal is doing what's it's designed to do. [We'll leave the debate about the magnitude of GL3-lowering effect for another time.]

I can't wait to see in February how a median 6% reduction in kidney GL3 led to nine of 32 placebo patients posting a response of greater than 50% reduction. Those nine placebo patients must have been super-duper responders.

Also important: 12-month kidney response rates from the study. We'll want to see if the GL3 reductions seen in Amigal-treated patients remains or improves further, while placebo patients switched to Amigal at six months show similar improvements.

Until then, Amicus is down but not yet out.

I couldn't close the Mailbag for 2012 without one more comment on Amarin (AMRN) and its prescription fish-oil pill Vascepa.

Anyone still fixated -- mistakenly -- on the idea that Amarin is going to be bought out imminently should read Forbes' Matt Herper's take on the negative results announced Thursday from a large cardiovascular outcomes study of Merck's (MRK) niacin combination pill Tredaptive.

The fallout from the failed Merck study -- the niacin combination pill didn't reduce heart attacks, strokes and deaths and caused more serious adverse events -- is now engulfing Amarin.

No drug maker will open its wallet to buy Amarin without first seeing positive data from the ongoing Vascepa outcomes study in high triglyceride patients. Unfortunately for Amarin, that study won't be completed until 2016.

Moreover, I'd say odds that FDA approves an expansion of Vascepa label into the "Anchor" population of high triglyceride patients just went down. I could see FDA wanting to see positive data from the outcomes study as pre-approval requirement following the failure of the Merck Tredaptive study.

Dave J. asks, "Is there any value left in Oncothyreon (ONTY) now that Stimuvax has failed? Where do you see the stock trading in the coming months?"

Let's start the discussion with the baseline assumption that Stimuvax is dead, as is ONT-10, the company's next-generation cancer immunotherapy. Maybe you believe there's life still in these drugs, but the market certainly won't.
2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMRN $2.02 -1.90%
FOLD $7.02 9.90%
ONTY $2.80 -1.80%
AAPL $109.72 -0.60%
FB $93.90 2.00%


Chart of I:DJI
DOW 16,660.37 +188.00 1.14%
S&P 500 1,974.65 +23.29 1.19%
NASDAQ 4,750.8370 +43.0620 0.91%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs